Medivation, Inc. (MDVN) is on the rise during Monday's after-hours trading following news that its investigational drug Dimebon significantly improved cognitive function in patients with mild-to-moderate Huntington's disease.
At 4:32 pm ET the stock is trading at $14.50 up $2.39 from Monday's close.
With the advance, the stock stands to open having halted a recent downtrend and at its highest level in nearly a month.
For comments and feedback contact: editorial@rttnews.com
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.